30 closest matches · ranked by relevance
Thrombotic Microangiopathies
Primary: Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA — 0; 0; 27 Participants
Thrombotic Microangiopathies · Atypical Hemolytic Uremic Syndrome · Multiple Organ Dysfunction Syndrome
Primary: Survival — 15 Participants — p=<0.0001
Thrombotic Microangiopathies
Primary: Percent of Total Doses of Defibrotide That Were Missed [Feasibility] — 0.7 percentage of missed doses
Thrombotic Microangiopathies · Hematologic Diseases
Primary: The Incidence of TA-TMA. — 5; 15 Participants
Thrombotic Thrombocytopenic Purpura
Primary: Incidence of the Composite Primary Outcome of Exacerbation or Refractory TTP — 2; 0 Participants
Transplant-Associated Thrombotic Microangiopathy
Primary: Pegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau) — 14934.65; 20089.79; 36208.37 µg*h/mL
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time to Platelet Count Response — 2.69; 2.88 days — p== 0.0099
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Thrombotic Thrombocytopenic Purpura (TTP)
Primary: Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events During Prophylactic Treatment — 0; 0; 1 Participants
Aortic Stenosis · Inflammation · Thrombosis
Primary: Platelet Reactivity — 275.5; 251; 234; 128.5 Platelet Reactivity Units
Thrombotic Thrombocytopenic Purpura
Primary: Number of Participants With Exacerbations in the CSA/PEX Arm Compared to the Steroids/PEX Arm — 3; 1 participants
Thrombotic Thrombocytopenic Purpura
Primary: Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study Period — 93.5 percentage of participants
Atypical Hemolytic-Uremic Syndrome
Primary: Percentage of Patients With Complete TMA Response — 73.2 Percentage of Participants
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Primary PCI for STEMI
Primary: Rate of Complete ST-segment Elevation Resolution at 60 Minutes After the End of the Procedure — 38; 58 Participants
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants
Liver Transplantation · Kidney Transplantation
Primary: Delayed Kidney Graft Function — 5; 7 Participants
Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 7; 1 Participants
Atypical Hemolytic-Uremic Syndrome
Primary: Proportion of Patients With Complete TMA Response — 63.6 Percentage of Participants
Anemia, Aplastic · Anemia, Hypoplastic · Thrombocytopenia
Primary: The Portion of Drug Responders as Defined by Hematologic Improvements — 17 Participants
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Hematologic Neoplasms · Hemorrhage · Hematopoietic Stem Cell Transplantation
Primary: The Proportion of Patients Who Die or Have Bleeding of WHO Grade 2 or Above by WHO Criteria During the First 30 Days From the First Dose of Trial Treatment, or Planned…
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time-to-response of Treatment Defined by a Confirmed Recovery of Platelets ≥ 150,000/µL — 2.4; 4.3; 3; 4.9 days — p== 0.005
Heart Attack
Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…
ST-segment Elevation Myocardial Infarction
Primary: Postinfarct Remodeling — 11; 6 Number of participants with remodeling
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
Autoimmune Diseases · Renal Disorders · Hematologic Disorders
Primary: Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure — 81.9; 75.2 percentage of plasma removal efficiency — p=<0.001
Thrombocytopenia · Acute Radiation Syndrome
Primary: Maximum Tolerated Dose (MTD) of Eltrombopag — 300 mg/day
Myocardial Infarction
Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL